drugset

drugset / Trial / NCT03202303

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

NCT03202303 ↗

Phase 2 Recruiting 100 enrolled Montefiore Medical Center GW Pharmaceuticals Ltd · collab Jazz Pharmaceuticals · collab United States Department of Defense · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

Timeline

Start: 2019-04-12
Primary completion: 2027-02
Completion: 2027-02

Publications

Ferretti CJ, Cook BL, Mahant AM, Chu P, Zhao Y, Taylor BP, Herold BC, Hollander E. Cognitive inflexibility and immunome biomarkers in children with autism spectrum disorder. Neurosci Appl. 2024 May 4;3:104071. doi: 10.1016/j.nsa.2024.104071. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidivarin	Small molecule	10 mg/kg	—

Indications